Trial Profile
Randomized, Placebo-controlled, Double-blind Phase I Dose-escalating Trial to Evaluate the Safety and Immunogenicity of a Vaccine Against Human Cytomegalovirus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs HB 101 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; First in man
- Sponsors Hookipa Biotech; Hookipa Pharma
- 21 Apr 2020 Results presented in a Hookipa Pharma media release.
- 21 Apr 2020 According to a Hookipa Pharma media release, results from the study have been published in The Journal of Infectious Diseases. Results are available online in the journal.
- 12 Apr 2020 Results published in the Journal of Infectious Diseases